In the dark days of the coronavirus pandemic, Moderna (NASDAQ: MRNA) was a ray of light in more ways than one. The healthcare company's innovative Spikevax was one of the go-to vaccines that sped ...
We recently published a list of 10 Firms Kick Off Shortened Trading Week With Impressive Gains. In this article, we are going ...
We recently published a list of Five Chinese Firms Dominate Friday’s Top 10 Gainers. In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA) stands against the other friday’s ...
While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...
Biotechnology company Moderna (NASDAQ:MRNA) in Q4 CY2024, but sales fell by 65.6% year on year to $966 million. On the other ...
As bad as it may look on the charts, Moderna’s (NASDAQ: MRNA) post-COVID let-down and market reset are over. The company ...
2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the fourth quarter and fiscal year 2024. "We have made progress in 2024 across our late-stage ...
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 ...
In the preceding three months, 11 analysts have released ratings for Moderna (NASDAQ:MRNA), presenting a wide array of perspectives from bullish to bearish. The table below offers a condensed view ...
Moderna (NASDAQ:MRNA), the biotech company known for its Spikevax COVID-19 vaccine, released its fourth-quarter earnings on Feb. 14. The results revealed significant financial challenges as the ...
Looking at options history for Moderna (NASDAQ:MRNA) we detected 32 trades. If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish ...
In the dark days of the coronavirus pandemic, Moderna (NASDAQ: MRNA) was a ray of light in more ways than one. The healthcare ...